Form 4 for CTKB Cytek Biosciences, Inc.

Accepted 2022-03-08 00:00:00 ET · period of report 2022-03-04 · accession 0001104659-22-031596 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MI	2022-03-08	2022-03-04+	CTKB	Shah Rajeev M.	Dir	P - Purchase	$12.74	+647.3K	11.92M	+6%	+$8.25M

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-03-08	P	A	245,701	$12.86	12,162,546	I See footnotes	—	—	(F6) This transaction was executed in multiple trades at prices ranging from $12.12 to $13.00; the price reported above reflects the weighted average purchase price. (F7) These securities include 10,469,055 shares held directly by the Fund, 1,185,767 shares held by Nexus Fund II, and 507,724 shares held by the Account. (F8) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund II and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
2	Common	Common Stock	2022-03-04	P	A	63,662	$12.99	11,578,944	I See footnotes	—	—	(F2) This transaction was executed in multiple trades at prices ranging from $12.93 to $13.00; the price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. (F3) These securities include 9,885,453 shares held directly by RA Capital Healthcare Fund, L.P. (the "Fund"), 1,185,767 shares held by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and 507,724 shares held by a separately managed account (the "Account"). (F8) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund II and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
3	Common	Common Stock	2022-03-07	P	A	337,901	$12.61	11,916,845	I See footnotes	—	—	(F4) This transaction was executed in multiple trades at prices ranging from $12.31 to $13.00; the price reported above reflects the weighted average purchase price. (F5) These securities include 10,223,354 shares held directly by the Fund, 1,185,767 shares held by Nexus Fund II, and 507,724 shares held by the Account. (F8) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund II and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.